Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated interferon alpha 2b + 3BNC117 + 10-1074
- Development stage
- Phase 1
- Lead developer
- The Wistar Institute
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
This investigational combination therapy consists of pegylated interferon alpha 2b (peg-IFN-α2b) and two broadly neutralizing antibodies (bNAbs), 3BNC117 and 10-1074. Developed as part of the BEAT-2 clinical trial led by Luis Montaner at The Wistar Institute, the regimen is designed to achieve sustained HIV-1 viral suppression and reduce the latent viral reservoir in patients undergoing an analytical treatment interruption (ATI). Pegylated interferon alpha 2b acts as an immune modulator that stimulates innate immune responses and exerts direct antiviral effects. The bNAbs 3BNC117 and 10-1074 target the CD4 binding site and the V3 loop/glycan supersite of the HIV-1 envelope glycoprotein gp120, respectively, to neutralize the virus and potentially enhance the clearance of infected cells through effector functions.
- Other names
- peg-IFN-α2b + 3BNC117 + 10-1074Pegylated Interferon alpha 2b + 3BNC117 + 10-1074
02
Targets
gp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)Env (HIV-1 envelope glycoprotein)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on pegylated interferon alpha 2b + 3BNC117 + 10-1074.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated interferon alpha 2b + 3BNC117 + 10-1074.